Search
Avidity Biosciences Inc
RNAAdd to Watchlist
13.650USD
+0.350+2.63%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
233.49MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.63%
5 Days
+3.49%
1 Month
+10.98%
6 Months
-81.07%
Year to Date
-81.08%
1 Year
-53.21%
Key Figures
13.400Open
13.715High
196.85KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.15%Turnover Ratio
13.300Prev. Close
13.200Low
2.12MTurnover
LossP/E Static
1.00P/B
0.00%Div Yield TTM
-38.88%ROA
16.77052wk High
0.92Volume Ratio
-322.30MNet Profit
17.11MShares
-2.8924EPS TTM
--Beta
-43.98%ROE
11.95052wk Low
3.87%Amplitude
100.00%Gross Margin
233.49MMarket Cap
2.61Reward/Risk
3.11%Risk Rate
TradingKey Stock Score of Avidity Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Avidity Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avidity Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Avidity Biosciences Inc Highlights
StrengthsRisks
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 94.75% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.62M.
Overvalued
The company’s latest PE is -4.72, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.97M shares, increasing 42.34% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 22.58K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
25.000
Target Price
+87.97%
Upside Space
Avidity Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Avidity Biosciences Inc Info
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Ticker SymbolRNA
CompanyAvidity Biosciences Inc
CEOBoyce (Sarah)
Websitehttps://www.aviditybiosciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Avidity Biosciences Inc (RNA)?
The current price of Avidity Biosciences Inc (RNA) is 13.65.
What is the symbol of Avidity Biosciences Inc?
The ticker symbol of Avidity Biosciences Inc is RNA.
What is the 52-week high of Avidity Biosciences Inc?
The 52-week high of Avidity Biosciences Inc is 16.77.
What is the 52-week low of Avidity Biosciences Inc?
The 52-week low of Avidity Biosciences Inc is 11.95.
What is the market capitalization of Avidity Biosciences Inc?
The market capitalization of Avidity Biosciences Inc is 233.49M.
Is Avidity Biosciences Inc (RNA) currently rated as Buy, Hold, or Sell?
According to analysts, Avidity Biosciences Inc (RNA) has an overall rating of Buy, with a price target of 25.00.
What is the Earnings Per Share (EPS TTM) of Avidity Biosciences Inc (RNA)?
The Earnings Per Share (EPS TTM) of Avidity Biosciences Inc (RNA) is -2.89.